Esperion (NASDAQ:ESPR) Therapeutics were seen rising as much as 23% on Monday. This notable surge, the largest intraday gain in approximately a year, followed the company's announcement regarding its submission of New Drug Submissions (NDSs) to Health Canada for two of its cholesterol treatments, Nexletol and Nexlizet.
The company's strategic efforts to broaden the availability of its products in various markets have been recognized by industry analysts.
Joseph Pantginis, an analyst at HC Wainwright, commented on Esperion's recent moves, stating that the company's focus on expanding access to its cholesterol treatments in both established and emerging markets is well-positioned to drive meaningful long-term growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.